3709-98-6

Usage

Uses

Used in Pharmaceutical Synthesis:
4(1H)-Pyrimidinone, 2-ethyl-6-hydroxy(9CI) is utilized as a key intermediate in the development of pharmaceuticals due to its ability to be incorporated into the molecular structures of various drugs. Its presence in drug molecules can contribute to enhancing their therapeutic effects and pharmacological profiles.
Used in Agrochemical Production:
In the agrochemical industry, 4(1H)-Pyrimidinone, 2-ethyl-6-hydroxy(9CI) serves as a building block for the synthesis of compounds with pesticidal or herbicidal properties. Its integration into these chemical products can improve their efficacy in agricultural applications.
Used in Organic Chemistry Research:
4(1H)-Pyrimidinone, 2-ethyl-6-hydroxy(9CI) is employed as a reactant in organic chemistry research, where it can participate in a range of chemical reactions to form new organic compounds. Its reactivity and structural features make it a useful tool for exploring novel synthetic pathways and developing innovative organic molecules.
Used in Material Science:
In the field of material science, 4(1H)-Pyrimidinone, 2-ethyl-6-hydroxy(9CI) is used for its potential to contribute to the development of new materials with specific properties. Its incorporation into material formulations can lead to advancements in areas such as polymer science, where it may enhance material characteristics like stability, reactivity, or biological activity.
Overall, 4(1H)-Pyrimidinone, 2-ethyl-6-hydroxy(9CI) is a multifaceted chemical entity with broad applications across different scientific and industrial domains, underscoring its importance in modern chemical innovation.

InChI:InChI=1/C6H8N2O2/c1-2-4-7-5(9)3-6(10)8-4/h3H,2H2,1H3,(H2,7,8,9,10)

Upstream product

• 108-59-8 malonic acid dimethyl ester 
• 3599-89-1 propionamidine hydrochloride 
• 105-53-3 diethyl malonate 

Downstream Products

• 1269117-06-7 2-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-7-methyl-5-(1-methylethoxy)-4-oxo-3-(2-oxo-2-phenylethyl)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-6-carboxamide 
• 1269118-48-0 ethyl 4-chloro-2-ethyl-5-hydroxy-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate 
• 1269118-94-6 ethyl 3-(3-chlorobenzyl)-2-ethyl-7-methyl-5-(1-methylethoxy)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-6-carboxylate 
• 1269116-89-3 2-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-7-methyl-4-oxo-3-(2-oxo-2-phenylethyl)-5-(2,2,2-trifluoroethoxy)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-6-carboxamide 
• 1195-34-2 4,6-dichloro-2-ethylpyrimidine 

Relevant academic research and scientific papers

Synthesis and evaluation of hedgehog signaling inhibitor with novel core system

As we previously reported, N-methylpyrrolo[3,2-c]pyridine derivatives 1 (TAK-441) was discovered as a clinical candidate of hedgehog (Hh) signaling inhibitor by modification of the upper part. We next focused on modification of the lower part including core skeletons to discover new Hh signaling inhibitors with novel core rings. Efforts to find novel chemotypes by using X-ray single crystal structure analysis led to some potent Hh signaling inhibitors (2c, 2d, 2e, 2f) with novel core ring systems, which had benzamide moiety at the 5-position as a key component for potent activity. The suppression of Gli1 expression with these new Hh signaling inhibitors were weaker than that of compound 1 (TAK-441) because of low pharmacokinetic property. We recognized again TAK-441 is a good compound as clinical candidate with good structural and pharmacokinetic advantages.

PYRIMIDINE PDE10 INHIBITORS

The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.

Pyrimidines substituted by nitrogen-containing heterocyclic rings as intermediates

1,2,4-Triazolo[4,3-c]pyrimidines substituted at the 5 or 7 position through a nitrogen atom which is part of a heterocyclic ring have been found to have potent bronchodilator activity and to be useful synthetic intermediates in the preparation of 1,2,4-triazolo[1,5-c]pyrimidines. Methods for inducing bronchodilation, pharmaceutical compositions, and synthetic processes and intermediates are also described.

Triazolo [4,3-c]pyrimidines substituted by nitrogen-containing heterocyclic rings

1,2,4-Triazolo[4,3-c]pyrimidines substituted at the 5 or 7 position through a nitrogen atom which is part of a heterocyclic ring have been found to have potent bronchodilator activity and to be useful synthetic intermediates in the preparation of 1,2,4-triazolo[1,5-c]-pyrimidines. Methods for inducing bronchodilation, pharmaceutical compositions, and synthetic processes and intermediates are also described.